Navigation Links
Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine
Date:9/21/2011

BROOMFIELD, Colo., Sept. 21, 2011 /PRNewswire/ -- Ariel Pharmaceuticals, Inc., a private, specialty pharmaceutical company focused on the development and commercialization of products for acute central nervous system (CNS) diseases and trauma, announced today that it has in-licensed its lead product, AP-1531, for the treatment of acute migraine attacks, from the specialist healthcare company BTG International Ltd (LSE: BGC).

While the precise cause of migraines is not fully understood, changes in vascular tone and inflammatory processes appear to be key contributing factors.  Prostaglandins are naturally existing molecules that are integral components of both vascular and inflammatory reactions in the central and peripheral nervous systems.   There is evidence to demonstrate that prostaglandin E2 (PGE2) binding to the EP4 receptor causes dilation of small blood vessels in the brain, while leaving coronary and pulmonary arteries unaffected, and can stimulate a variety of inflammatory mechanisms.  AP-1531 is a potent and selective EP4 receptor antagonist that specifically targets PGE2-EP4 binding which may treat migraines. AP-1531 has shown promising results  in several disease models of migraine and acute pain and inflammation.  

"We are extremely pleased with the data from six Phase I studies on AP-1531 and are confident this approach will yield positive results as we initiate a Phase 2 study in migraine patients in 2012," said Steve Orndorff, President and CEO of Ariel Pharmaceuticals.  "Given that the current standard of care for moderate to severe migraines can take up to 90 minutes to provide relief and works temporarily or not at all in many patients, in addition to having potentially serious side effects, we're committed to developing a safer and more efficacious alternative that will provide better quality care to patients.  We believe AP-1531 will validate our business model of in-licensing clinic-ready drugs in acute care clinical indications to expeditiously build value for our shareholders."

Episodic migraine headaches affect more than 10% of the world population and are among the top four disabling neurological conditions.  Migraines account for an estimated 30 million days of lost productivity at a cost of up to $17 billion per year in the U.S.  Almost half of migraine patients suffer severe pain and require bed rest.  Currently, the most common migraine therapies are non-steroidal anti-inflammatory drugs (NSAIDs) and triptans (5-HTIB/1D agonists).  Shortcomings of these drugs include failure to work in a significant percentage of patients, slow speed of activity, recurrence of pain and potentially debilitating side effects, including cardiovascular and gastrointestinal toxicity.

About Ariel Pharmaceuticals, Inc.

Ariel Pharmaceuticals, Inc. is a private, specialty pharmaceutical company focused on the development and commercialization of drugs that improve quality of life for patients with acute neurological disorders and trauma.  Ariel is developing three drugs intended to meet unmet medical needs in migraine, hemorrhagic shock and post-operative cognitive decline.  The company's business strategy is based on in-licensing clinic-ready drugs in acute care clinical indications that have well-defined efficacy endpoints and where there is little to no competition in order to enable Ariel to rapidly build shareholder value.  For more information, please visit: www.arielpharma.com

Ariel Pharmaceuticals, Inc.
Steve Orndorff, PhD
President & CEO
sorndorff@arielpharma.com

Media Contact:
Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach
amielach@tiberend.com
or
Jason Rando
jrando@tiberend.com


'/>"/>
SOURCE Ariel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ariel Ways GovBuys Awarded VA Contract
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
7. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... YORK , Feb. 24, 2017 ... Monteverde & Associates PC , a boutique securities firm ... New York City , announces that a class ... Massachusetts  against Inotek Pharmaceuticals Corporation ... of the Company,s securities between July 23, 2015 and December ...
(Date:2/24/2017)...  Directors from Pharma To Market Pty Ltd and Ador Consulting ... in the founding of Pharma To Market Pte Ltd, based in ... pleased to announce their expansion into Asia ... . The company are delighted to appoint Joelle Chia , ... Singapore based entity. Joelle brings with her an extensive ...
(Date:2/24/2017)...  Xynomic Pharmaceuticals, Inc., an oncology drug research ... acquired exclusive worldwide rights to develop, manufacture and ... targeting hematological and solid tumors. To ... 2 clinical trials of Abexinostat in US, EU ... been completed, demonstrating that Abexinostat is clinically active ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 top five ... art competition. Selected from 15 submissions from around the nation, the top five finalists ... iaedp Symposium, March 22 – 26 in Las Vegas. , This year, the competition ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... specializes in thought leadership , media relations, social media, content marketing and ... will be powered through Act-On, an intuitive marketing automation platform. , Rosica will ...
(Date:2/23/2017)... Austin, TX (PRWEB) , ... February 23, 2017 ... ... has announced an official 2017 partnership with The Jensie Gran Fondo of Marin. ... UVA and UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... return to the La Gorce Country Club in Miami Beach to host its ...
(Date:2/23/2017)... ... 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will ... to Hot,” which will begin airing on February 24, 2017. The show chronicles the ... 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from TLC ...
Breaking Medicine News(10 mins):